Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Autor: Sibylle Boehmer, Lars Franzén, Robert E. Coleman, Joe M. O'Sullivan, Rui Li, Steffen Wedel, Isabel Syndikus, John P Logue, Mihalj Seke, David Bottomley, Ales Chodacki, Oliver Sartor, Daniel Heinrich, Sophie D. Fosså, Nicholas D. James, Marcos F. Dall'Oglio, Paweł Wiechno, K. Staudacher, Sten Nilsson, Peter Hoskin, Arne Solberg, Nicholas J. Vogelzang, Oana Petrenciuc, Svein Inge Helle, Anders Widmark, Ján Kliment, Øyvind S. Bruland, Dag Clement Johannessen, Chris Parker

Publikováno v: Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology, vol. 73, pp. 427-435 . https://doi.org/10.1016/j.eururo.2017.06.021
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Translational Andrology and Urology
Parker, C C, Coleman, R E, Sartor, O, Vogelzang, N J, Bottomley, D, Heinrich, D, Helle, S I, O'Sullivan, J M, Fosså, S D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D C, Hoskin, P, James, N D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Bruland, Ø S, Petrenciuc, O, Staudacher, K, Li, R & Nilsson, S 2017, ' Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial ', European Urology . https://doi.org/10.1016/j.eururo.2017.06.021

BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18d23aabdbd329a4ac3ee0a9d5e41fe
https://doi.org/10.1016/j.eururo.2017.06.021

Positive rate of canine pancreatic lipase immunoreactivity (SNAP cPL) in relationship with severity of clinical signs and concurrent disorders: a retrospective study.

Autor: Jongjin Park¹, Solji Choi¹, Young Min Yun^1,2, Myung-Chul Kim^2,3 mck@jejunu.ac.kr, Woo-Jin Song^1,2 ssong@jejunu.ac.kr

Publikováno v: Korean Journal of Veterinary Research. Sep2024, Vol. 64 Issue 3, p1-6. 6p.

Integraler baulicher Erdbebenschutz II: Definition des Lastfalls Erdbeben

Autor: K. Staudacher

Integraler baulicher Erdbebenschutz III: Baulicher Erdbebenschutz an einem Wendepunkt?

Autor: K. Staudacher

Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)

Autor: Nicholas J. Vogelzang, A.J. Lloyd, Robert E. Coleman, A. O. Sartor, Sten Nilsson, R. van Gool, Chris Parker, K. Staudacher

Publikováno v: Annals of Oncology. 23:ix296

Introduction Ra-223 is a first-in-class alpha-emitter pharmaceutical that targets bone metastases with high-energy, very short range ( Methods Eligible pts previously received or refused docetaxel, or were docetaxel ineligible, and were randomized 2:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e7dd449176742b845e662a4dfb7c31e
https://doi.org/10.1016/s0923-7534(20)33503-1